Welcome to
Prosigna is 510(k) cleared and CE marked. Prosigna is available to healthcare professionals in the United States, in markets that recognize the CE mark, and/or in which Prosigna is registered.
I am a healthcare professional in the US
I am a healthcare professional outside the US

Now included 4 Clinical Practice Guidelines

Home
This site is intended for US residents only.

Accurately determine risk of recurrence with Prosigna

Prosigna Scores correlate with 10-year probability of distant recurrence

  • The Prosigna Scores for a cohort of postmenopausal women with hormone receptor–positive, early-stage breast cancer were compared to distant recurrence-free survival (DRFS) following surgery and treatment with 5 years of adjuvant endocrine therapy followed by 5 years of observation (see Data summary)
  • This study resulted in a model relating the Prosigna Score to the probability of distant recurrence in 2 tested patient populations (node negative and node positive), including a 95% confidence interval
10-year predicted breast cancer recurrence probability estimated within nodal status group
Reference: 1. Prosigna [Package Insert]. Seattle, WA: NanoString Technologies, Inc; 2013.